Cinacalcet for the treatment of primary hyperparathyroidism

American Journal of Therapeutics

Volumn 18, Issue 4, 2011, Pages 313-322

  Dillon, Melanie L ^a,b   Frazee, Lawrence A ^a,b  

^a AKRON GENERAL MEDICAL CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

calcimimetics; Cinacalcet; treatment of primary hyperparathyroidism

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITONIN; CALCITRIOL; CALCIUM; CALCIUM ION; CINACALCET; CONJUGATED ESTROGEN; CREATININE; ETHINYLESTRADIOL; MEDROXYPROGESTERONE; NORETHISTERONE; PARATHYROID HORMONE; PLACEBO; RALOXIFENE;

ALKALINE PHOSPHATASE BLOOD LEVEL; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CALCITONIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DEPRESSION; DIET SUPPLEMENTATION; DRUG DOSE TITRATION; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FOLLOW UP; HEART ARRHYTHMIA; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MEDLINE; MENOPAUSAL SYNDROME; MULTICENTER STUDY (TOPIC); NEPHROLITHIASIS; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PANCREATITIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PEPTIC ULCER; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PSEUDOGOUT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SECONDARY HYPERPARATHYROIDISM; STROKE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIMIMETIC AGENTS; CALCITONIN; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; NAPHTHALENES; OSTEOPOROSIS; RALOXIFENE;

EID: 79960559611     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181bdc3d0     Document Type: Review

References (38)

1. Hatfield E, Turner J. Hypercalcaemia and primary hyperparathyroidism. Medicine. 2005;33:52-54.
2. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract. 2005;11: 49-54.
3. Elaraj DM, Clark OH. Current status and treatment of primary hyperparathyroidism. Permanente J. 2008;12: 32-37.
4. Marx SJ. Hyperparathyroid and hypoparathyroid disor-ders. N Engl J Med. 2000;343:1863-1875.
5. Bilezikian JP, Brandi ML, Rubin M, et al. Primary hyperparathyroidism: new concepts in clinical, desitometric and biochemical features. J Intern Med. 2005;257: 6-17. (Pubitemid 40129122)
6. Bilezikian JP, Silverberg SJ. Primary hyperparathyroid-ism: epidemiology and clinical consequences. Clin Rev Bone Metab. 2002;1:25-34. (Pubitemid 37013693)
7. Davies M, Fraser WD, Hosking DJ. The management of primary hyperparathyroidism. Clin Endocrinol. 2002;57: 145-155. (Pubitemid 34989089)
8. Vestergaard P. Current pharmacological options for the management of primary hyperparathyroidism. Drugs. 2006;66:2189-2211. (Pubitemid 44878528)
9. Bilezikian JP, Silverberd SJ. Asymptomatic primary hyperparathyroidism. N Engl J Med. 2004;350:1746-1751. (Pubitemid 38501143)
10. Hedback G, Oden A. Recurrence of hyperparathyroidism; a long-term follow-up after surgery for primary hyper-parathyroidism. Eur J Endocrinol. 2003;148:423-421.
11. Westerdahl J, Bergenfelz A. Parathyroid surgical failures with sufficient decline of intraoperative parathyroid hormone levels. Arch Surg. 2006;141:589-594.
12. Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med. 2008;75:739-750.
13. Wuthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest. 2007;37:915-922. (Pubitemid 350151180)
14. Marcus R, Madvig P, Crim M, et al. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med. 1984;100:633-640. (Pubitemid 14143934)
15. Selby PL, Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med. 1986;314: 1481-1485. (Pubitemid 16114664)
16. Diamond T, Ng AT, Levy S, et al. Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report. Osteoporos Int. 1996;6:329-333. (Pubitemid 26280829)
17. Guo Cy Thomas W, Eastell R. Longitudinal changes of bone mineral density in primary hyperparathyroidism [Abstract]. Bone. 1995;16:679-695.
18. Grey AB, Stapleton JP, Evans MC, et al. Effect of hormone replacement therapy on bone mineral density in post-menopausal women with mild primary hyperparathy-roidism: a randomized controlled trial. Ann Intern Med. 1996;125:360-368. (Pubitemid 126449705)
19. Orr-Walker BJ, Evans MC, Clearwater JM, et al. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathy-roidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med. 2000; 160:2161-2166. (Pubitemid 30482723)
20. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002; 288:321-333. (Pubitemid 34761611)
21. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated estrogens in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA. 2004;291:1701-1712. (Pubitemid 38489892)
22. Zanchetta JR, Bogado CE. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic pri-mary hyperparathyroidism. J Bone Miner Res. 2001;16: 189-190. (Pubitemid 32046205)
23. Rubin MR, Lee KH, McMahon DJ, et al. Raloxifene lowers serum calcium and markers of bone turnover in post-menopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:1174-1178. (Pubitemid 36337773)
24. Hassani S, Braunstein GD, Seibel MJ, et al. Alendronate therapy of primary hyperparathyroidism. Endocrinologist. 2001;11:459-464. (Pubitemid 33144151)
25. Rossini M, Gatti D, Isaia G, et al. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 2001;16:113-119. (Pubitemid 32046195)
26. Parker CR, Blackwell PJ, Fairbairn KJ, et al. Alendronate in the treatment of primary hyperparathryoid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab. 2002; 87:4482-4489. (Pubitemid 35247029)
27. Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endo-crinol Metab. 2003;88:581-587. (Pubitemid 36207794)
28. Khan AA, Bilezikian JO, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, random-ized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319-3325. (Pubitemid 38951898)
29. Torring O, Bucht E, Sjostedt U, et al. Salmon calcitonin treatment by nasal spray in primary hyperparathyroid-ism. Bone. 1991;12:311-316.
30. Stone MD, Marshall DH, Hosking DJ, et al. Comparison of low-dose intramuscular and intravenous salcatonin in the treatment of primary hyperparathyroidism. Bone. 1992;13:265-271.
31. Dong BJ. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005;27: 1725-1751. (Pubitemid 41815225)
32. Joy MJ, Kshirsagar AV, Franceschini N. Calcimimetics and the treatment of primary and secondary hyperparathy-roidism. Ann Pharmacother. 2004;38:1871-1880. (Pubitemid 39425725)
33. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endo-crinol Metab. 2003;88:5644-5649. (Pubitemid 38033028)
34. Peacok M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endo-crinol Metab. 2005;90:135-141. (Pubitemid 40116646)
35. Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metab Clin Exp. 2008;57:517-521. (Pubitemid 351317967)
36. Moyes V, Alexandraki K, Monson J, et al. Cinacalcet is an effective and well tolerated treated for MEN1 associated primary hyperparathyroidism. Endocrin Abstr. 2008;15.
37. Iglesias P, Ais G, Gonzalez A, et al. Acute and one-year effects of cinacalcet in patients with persistant primary hyperparathyroidism after unsuccessful parathyroidec-tomy Am J Med Sci. 2008;335:111-114. (Pubitemid 351253406)
38. Marcocci C, Chanson P, Shoback D, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrin Metab. 2009;94:2766-2772.